参考文献/References:
[1]Hallowell RW,Ascherman DP,Danoff SK.Pulmonary manifestations of polymyositis/dermatomyositis[J].Semin Respir Crit Care Med,2014,35(2):239-248.[2]Marie I.Morbidity and mortality in adult polymyositis and dermatomyositis[J].Curr Rheumatol Rep,2012,14(3):275-285.[3]Wei-Ming Y,Wei-Heng Z,Hou-Qun Y,et al.Two new inflammatory markers associated with disease activity score-28 in patients with rheumatoid arthritis:Albumin to fibrinogen ratio and C-reactive protein to albumin ratio[J].International Immunopharmacology,2018(62):293-298.[4]Qin B,Ma N,Tang Q,et al.Neutrophil to lymphocyte ratio(NLR)and platelet to lymphocyte ratio(PLR)were useful markers in assessment of inflammatory response and disease activity in SLE patients[J].Mod Rheumatol,2016,26(3):372-376.[5]Ha YJ,Hur J,Go DJ,et al.Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis:A retrospective observational study[J].PLoS One,2018,13(1):1-16.[6]Yang W,Wang X,Zhang W,et al.Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are 2 new inflammatory markers associated with pulmonary involvement and disease activity in patients with dermatomyositis[J].Clin Chim Acta,2017,465:11-16.[7]Kawasumi H,Gono T,Kawaguchi Y,et al.IL-6,IL-8,and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis[J].Biomed Res Int,2014,2014(1):1-6.[8]Gono T,Miyake K,Kawaguchi Y,et al.Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM[J].Rheumatology (Oxford)2012,51(7):1336-1338.[9]Dalakas MC,Longo DL.Inflammatory Muscle Diseases[J].New England Journal of Medicine,2015(372):1734-1747.[10]吴云娟,张晓军,张缪佳.联合检测3种肌炎特异性自身抗体在皮肌炎诊断中的意义[J].临床检验杂志,2013,31(6):422-424.[11]Hamaguchi Y,Fujimoto M.Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome[J].PLoS One,2013,8(4):1-11.[12]Mimori T,Nakashima R,Hosono Y.Interstitial lung disease in myositis:clinical subsets, biomarkers,and treatment[J].Curr Rheumatol Rep,2012,14(3):264-274.[13]Nakazawa M,Kaneko Y,Takeuchi T.Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis:a retrospective cohort study[J].Clin Rheumatol,2018,37(3):765-771.[14]Gono T,Sato S,Kawaguchi Y,et al.Anti-MDA5 antibody,ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis[J].Rheumatology,2012,51(1):1563-1570.[15]陈芳王,舒晓明.血清抗黑色素瘤分化相关基因抗体检测在多发性肌炎/皮肌炎患者中的意义[J].中华风湿病学杂志,2012,16(1):13-18.[16]Cao H.Pan M.Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody[J].Arthritis Care Res(Hoboken),2012,64(10):1602-1610.[17]Hall JC,Casciolarosen L,Samedy LA,et al.Anti-Melanoma Differentiation-Associated Protein 5-Associated Dermatomyositis:Expanding the Clinical Spectrum[J].Arthritis Care & Research,2013,65(8):1307-1315.[18]Marie I,Hatron PY,Dominique S,et al.Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis:a series of 107 patients[J].Arthritis Rheum,2011,63(11):3439-3447.[19]刘胜全,王巧玲,李云,等.多发性肌炎/皮肌炎肺损害的高分辨率CT诊断[J].实用放射学杂志,2012,28(5):671-674.[20]黎剑宇,邓宇,曾庆思,等.特发性非特异性间质性肺炎与结缔组织病相关性非特异性间质性肺炎的临床及HRCT比较[J].实用医学杂志,2017,33(15):2496-2500.[21]Knight E,Carne E,Novak B,et al.Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency[J].Journal of Clinical Pathology,2010,63(9):846-847.